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The Gram-negative periodontopathogen Aggregatibacter actinomycetemcomitans (Aa) binds
selectively to buccal epithelial cells (BECs) of human and Old World primates by means of the
outer-membrane autotransporter protein Aae. We speculated that the exposed N-terminal portion
of the passenger domain of Aae would mediate binding to BECs. By using a series of plasmids
that express full-length or truncated Aae proteins in Escherichia coli, we found that the BEC-
binding domain of Aae was located in the N-terminal surface-exposed region of the protein,
specifically in the region spanning amino acids 201–284 just upstream of the repeat region within
the passenger domain. Peptides corresponding to amino acids 201–221, 222–238 and 201–
240 were synthesized and tested for their ability to reduce Aae-mediated binding to BECs based
on results obtained with truncated Aae proteins expressed in E. coli. BEC-binding of E. coli
expressing Aae was reduced by as much as 50% by pre-treatment of BECs with a 40-mer
peptide (201–240; P40). Aae was also shown to mediate binding to cultured human epithelial
keratinocytes (TW2.6), OBA9 and TERT, and endothelial (HUVEC) cells. Pre-treatment of
epithelial cells with P40 resulted in a dose-dependent reduction in binding and reduced the
binding of both full-length and truncated Aae proteins expressed in E. coli, as well as Aae
expressed in Aa. Fluorescently labelled P40 peptides reacted in a dose-dependent manner with
BEC receptors. We propose that these proof-of-principle experiments demonstrate that peptides
can be designed to interfere with Aa binding mediated by host-cell receptors specific for Aae
adhesins.
INTRODUCTION
Aggregatibacter actinomycetemcomitans (Aa) has been the
subject of intense investigation since 1976 when it was
discovered to be associated with localized aggressive peri-
odontitis (LAP), an infection in young adolescents of
African descent, which can result in premature tooth loss
(Newman et al., 1976; Slots, 1976). Recently, this association
has become more compelling in light of two longitudinal
studies that have shown that healthy adolescents who
harbour Aa have a significantly greater risk of developing
disease than their age, gender-and race-matched controls
(Fine et al., 2007; Haubek et al., 2008). In conjunction with
these clinical studies, Aa has been shown to possess an array
of virulence traits that are consistent with the pathogenesis
of LAP. These traits include attachment and colonization
factors, innate and acquired host-defence avoidance factors,
and connective tissue and bone destructive factors (Fine
et al., 2006; Fives-Taylor et al., 1999; Henderson et al., 2002).
Aa attachment and colonization functions have been
assigned to a variety of outer-membrane proteins that
mediate binding to oral mucosal surfaces (Asakawa et al.,
2003; Komatsuzawa et al., 2002). As such, these structures
are presumed to be a prerequisite for Aa-initiated mucosal
infections (Asakawa et al., 2003; Komatsuzawa et al., 2002).
It has further been shown that Aa can be found in
atheromatous plaques, and is one of several periodontal
pathogensthat havebeenassociatedwithanincreasedriskof
heart disease (Haraszthy et al., 2000; Kozarov et al., 2005).
Taken together, these studies attest to the importance of
understanding how Aa initiates disease at a molecular level.
Our goal is to dissect the molecular events relating to
binding so that novel diagnostic, preventive and therapeutic
strategies can be discovered.
Abbreviations: Aa, Aggregatibacter actinomycetemcomitans; BECs,
buccal epithelial cells; FBS, fetal bovine serum; LAP, localized
aggressive periodontitis; HUVECs, human umbilical vein endothelial
cells.
The GenBank/EMBL/DDBJ accession number for the aae gene
sequence of Aggregatibacter actinomycetemcomitans strain IDH 781 is
FJ744750.
Two supplementary figures are available with the online version of this
paper.
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mucosa as a primary site for Aa colonization and immune
avoidance(Egeretal.,1996;Mu ¨lleretal.,1996;Rudneyetal.,
2001). Along these lines, we and others have shown that Aa
produces two autotransporter adhesins, Aae and ApiA, that
account for its association with the oral mucosal epithelium
(Asakawa et al., 2003; Fine et al., 2005; Komatsuzawa et al.,
2002; Rose et al., 2003; Yue et al., 2007). In vitro studies have
shown that if both the aae and apiA structural genes are
mutated, the attachment of Aa to buccal epithelial cells
(BECs)is completelyabrogated (Yue etal., 2007).Moreover,
Aa has been shown to attach to and penetrate endothelial
cells, although the cellular events that direct that attachment
are still unknown (Kusumoto et al., 2004; Schenkein et al.,
2000). It is our premise that both Aae and ApiA could be
instrumental in the attachment of Aa to tissues. Thus, the
more we understand about the role of Aae and ApiA in the
attachment of Aa to epithelial and endothelial surfaces, the
more we can direct our work towards designing strategies to
interfere with that attachment.
This study focused on the role of the autotransporter
adhesin Aae in the attachment of Aa to epithelial cells with
the goal of developing strategies to interfere with Aa
binding. Our plan was to revisit methods developed for
anti-adhesive therapeutic approaches to mucosal infections
(Beachey, 1981; Cheney et al., 1980; Sellwood et al., 1975).
It is well known that autotransporters contain three basic
functional domains: an N-terminal signal peptide that
directs the export of the protein through the inner
membrane by a Sec-dependent mechanism, a C-terminal
translocator domain that inserts into the outer membrane
and forms a b-barrel structure with a central channel, and
an internal passenger domain that is secreted through the
channel in the b-barrel and presented on the cell surface
(Henderson et al., 1998, 2004). Since the N-terminal
passenger domain is exposed to the environment external
to the bacterial cell, it is the likely region for binding to
host cells (Fine et al., 2005). The passenger domain of
autotransporter proteins often contains a series of repeat
sequences (Henderson & Nataro, 2001). In the case of Aae,
repeats in the passenger domain are clustered toward the
amino terminus, the number of repeats varying from one
to four depending on the strain (Fine et al., 2005; Rose
et al., 2003). The exact function of the Aae repeats is
unknown, but it is speculated that a greater number of
repeats may be related to an increased binding of Aa to its
target tissue (Rose et al., 2003). The goal of this work was
to locate the region of the Aae passenger domain that
influences Aa attachment to BECs and related epithelial
cells, with the long-term goal of defining the minimal motif
needed to prevent the initiation of disease.
METHODS
Bacterial strains and growth conditions. The bacterial strains
used in this study are listed in Table 1. Aa strains were cultured on
AAGM agar plates or in AAGM broth (Fine et al., 1999), except that
bacitracin and vancomycin were omitted from the media. All Aa
cultures were grown in 10% CO2. Escherichia coli strains were
cultured on Luria–Bertani (LB) agar plates or in LB broth. Media
were supplemented with kanamycin 50 mgm l
21; 1 mM IPTG was
added when necessary. E. coli cultures were incubated in air at 37 uC
with shaking (250 r.p.m.).
Construction of aae wild-type and deletion mutant plasmids.
We constructed plasmids containing wild-type aae and seven different
aae deletion mutants as follows. First, the full-length aae gene was
amplified by PCR using primers Aae-BamHI-F and Aae-PstI-R
(Table 1) and genomic DNA from Aa strain IDH 781 as a template.
The PCR product (2759 bp) was inserted into plasmid pCR2.1-TOPO
(Invitrogen) according to the manufacturer’s instructions. The
resulting plasmid, designated pGJD3, contained aae in the orientation
that placed the gene under control of the lac promoter. Next, IDH 781
genomic DNA was amplified by PCR with forward primer Aae-Acc65I
combined with reverse primers Aae-301, Aae-284, Aae-264, Aae-238,
Aae-221, Aae-201, Aae-120 and Aae-68 (Table 1) in eight different
PCRs (primerorientations aredescribedwithrespecttothedirectionof
transcription). Forward primers were engineered to contain an Acc65I
restriction site. The PCR products were digested with Acc65I and
Bpu10I and ligated into the Acc65I/Bpu10I restriction sites of pGJD3.
The Acc65I andBpu10I recognitionsequences correspond to bp 283 to
278 upstream of the aae start codon located in the backbone of
pCR2.1-TOPO in pGJD3, and bp 1783 to 1789 in the aae gene,
respectively (Fig. 1a). The ligation reactants were transformed into E.
coli DH5a chemically competent cells (Invitrogen) and transformants
were selected on LB agar supplemented with kanamycin. All plasmid
constructs were confirmed by restriction endonuclease digestion (Fig.
1b) and DNA sequence analysis.
Isolation of human buccal epithelial cells. Human buccal
epithelial cells (BECs) were collected from healthy adult volunteers
as previously described (Fine et al., 2005). Collection of BECs from
human volunteers was approved by the UMDNJ Institutional Review
Board. Cells were diluted to approximately 5610
4 c.f.u. ml
21 using a
haemocytometer. The absence of endogenous bacteria was confirmed
by spreading BECs onto LB plates containing kanamycin 50 mgm l
21
as well as on AAGM agar plates.
Buccal epithelial cell binding. The BEC binding assay was
performed as described previously (Fine et al., 2005; Yue et al.,
2007). Briefly, 48-h-old cultures of Aa strain IDH 781 were rinsed
three times with PBS, scraped from the culture dishes with a cell
scraper and then vigorously vortexed to disperse cell aggregates. The
E. coli cells were prepared by inducing exponential-phase cultures
with IPTG (final concentration of 1 mM) for 3 h. Aa or E. coli cells
were adjusted to OD590 0.8. A total of 200 mlo fAa or E. coli cells at a
concentration of ~10
9 c.f.u. ml
21 was added to 200 ml BECs (at a
concentration of 1610
5 cells ml
21) in a 1.5 ml microcentrifuge tube
to achieve a ratio of 10
4 bacterial cells per BEC. The tube was rotated
at 20 r.p.m. at 37 uC for 60 min. One hundred microlitres of the
mixture of bacteria and BECs was placed on the top of a 10 ml
gradient of 5% Ficoll 400 suspended in PBS contained in a 15 ml
centrifuge tube. The tube was centrifuged at 600 g for 10 min to
separate unbound bacteria from the heavier BECs, which pelleted to
the bottom of the tube. The supernatant was removed carefully by
pipette and the pellet was resuspended in 100 ml PBS. Resuspended
cells were serially diluted and plated on agar for c.f.u. enumeration.
Controls included BECs with no bacteria, and bacteria alone with no
BECs. Results were calculated as c.f.u. ml
21 and then converted to
c.f.u. per BEC.
Cell culture techniques. Cell lines were cultured in six-well or
twelve-well tissue culture plates (Becton/Dickinson). Cell line TW2.6,
a buccal epithelial cell line, was a kind gift from Dr Mark Y. P. Kuo
A. actinomycetemcomitans autotransporter adhesin
http://mic.sgmjournals.org 3413(School of Dentistry, National Taiwan University). TW2.6 buccal
epithelial cells were cultured in DMEM/Ham’s F12 medium (3:1)
(Gibco) with 5% antibiotics and 15% fetal bovine serum (FBS) as
previously described (Kok et al., 2007). An immortalized human
gingival epithelial cell line (OBA-9) and a human oral mucosal
keratinocyte line which ectopically expressed a telomerase catalytic
subunit (OKF6/TERT-1) were kind gifts from Dr Gill Diamond (New
Jersey Dental School). OBA-9 and OKF6/TERT-1 cells were cultured
in keratinocyte serum-free medium, supplemented with 0.05%
bovine pituitary extract and 5 ng recombinant epidermal growth
factor ml
21 (Invitrogen). Additional CaCl2 was added to the medium
to a final concentration of 0.4 mM (Kusumoto et al., 2004). Pooled
human umbilical vein endothelial cells (HUVECs) were purchased
from Lonza and cultured in EBM-2 complete medium according to
the manufacturer’s instructions, except that additional FBS was added
to attain a final concentration of 10%. All cell lines were cultured at
37 uC in a humidified atmosphere of 5% CO2 in air.
Binding of E. coli to cultured cells. Cell lines were cultured to
approximately 85–90% confluence. The cells were harvested by
trypsinization, washed once in PBS and adjusted to a concentration of
10
5 cells ml
21. The E. coli suspensions were prepared as described
above. After Ficoll separation, the resulting pellets were resuspended,
serially diluted and plated on LB agar containing kanamycin or
chloramphenicol (50 mgm l
21) in order to determine c.f.u. ml
21
which was then converted to bacterial cells ml
21.
Blocking epithelial cell binding with synthetic peptides. Three
peptides, P21 (AQKEAERLANEQEIARQKIKA), P17 (NELQRAI-
NEQSKLAEVA) and P40 (AQKEAERLANEQEIARQKIKANELQ-
RAINEQSKLAEVARV), were chemically synthesized, by CHI
SCIENTIFIC, to 99% purity. These peptides correspond to amino
acids 201–221, 222–238 and 201–240, respectively, in Aae. Peptides
were added to the cultured cells, after treatment with a blocking
buffer, to achieve a concentration of 0.1–100 mgm l
21. Control cells
were treated with no peptide. After 1 h at room temperature, bacteria
were added to the cells and the binding assay was performed as
described above.
Fluorescently labelled peptide binding assay. TW2.6 cells were
cultured in 96-well microtest tissue culture plates (Becton Dickinson).
When 85% confluence was achieved, cells were washed three times
with ice-cold HEPES buffer (50 mM HEPES, 128 mM NaCl, 5 mM
KCl, 5 mM MgSO4, 1.3 mM CaCl2, 5% heat-inactivated FBS).
HEPES buffer containing 3% BSA (blocking buffer) was added for
2 h to block non-specific binding. FITC-conjugated peptide P40
dissolved in HEPES buffer was added to the wells to achieve a
concentration of 0–250 mM. The plates were then incubated at room
temperature for 2 h. At the end of the incubation period, the cells
were rinsed three times with HEPES buffer and the fluorescence was
quantified by a Multi-Detection Microplate Reader (BIO-TEK
Instruments). The background level of binding was measured in
wells without TW2.6 cells.
Table 1. Bacterial strains, plasmids and PCR primers
Strain, plasmid or primer Relevant characteristics or sequence* Reference or source
Bacterial strains
A. actinomycetemcomitans IDH 781 Wild-type (serotype d) Fine et al. (2005)
A. actinomycetemcomitans JK 1047 IDH 781N flp-1::Tn903kan; Km
r Yue et al. (2007)
E. coli DH5a For expression of aae in E. coli New England Biolabs
Plasmids
pCR2.1 TOPO Cloning vector (Km
r) Invitrogen
pGJD3 pCR2.1 TOPO containing aae from Aa IDH 781 This study
pD301–594 pGJD3 with truncated aae (D301–596) This study
pD284–594 pGJD3 with truncated aae (D284–596) This study
pD264–594 pGJD3 with truncated aae (D264–596) This study
pD238–594 pGJD3 with truncated aae (D238–596) This study
pD221–594 pGJD3 with truncated aae (D221–596) This study
pD201–594 pGJD3 with truncated aae (D200–596) This study
pD68–594 pGJD3 with truncated aae (D67–596) This study
pVK43 pJAK16 containing aae from Aa CU 1000 (Cm
r) Fine et al. (2005)
PCR primersD
Aae-BamHI-F GCGCGGATCCATAATGAAGAAAGTTTAGATGTGTTCTTTTTCAAAAAAGT This study
Aae-PstI-R TGCGCTGCAGCTACCAGTAATTCAGTTTTACACC This study
Aae-Acc65I CCAAGCTTGGTACCGAGCTC This study
Aae-301 GATAACCTCAGCTTCTTCTGCCTTTTGA This study
Aae-284 GATAACCTCAGCTTCTAAACGCTTGCGTT This study
Aae-264 GATAACCTCAGCTTGTTGGCGAAGTATTTCA This study
Aae-238 GATAACCTCAGCAACTTCGGCTAATTTAC This study
Aae-221 GATAACCTCAGCTTTAATCTTTTGGCGGG This study
Aae-201 GATAACCTCAGCTGCCAGCTGCTCTTTA This study
Aae-120 GATAAACCTCAGCTTCTTTTTGTGCCATCTC This study
Aae-68 GATAACCTCAGCCTGAGAAGACGGTTGA This study
*Km
r, kanamycin resistant; Cm
r, chloramphenicol resistant.
DPCR primer sequences are shown in the 59A39 orientation. Restriction endonuclease cleavage sites are underlined. The aae start and stop codons
are shown in bold.
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One-way ANOVA comparison was followed by post-hoc Tukey–
Kramer testing for pairwise analysis. P-values ,0.05 were considered
significant.
RESULTS
Construction of plasmids encoding wild-type and
mutant Aae proteins
The aae gene from Aa strain IDH 781 was amplified by
PCR and then ligated into plasmid vector pCR2.1 TOPO,
resulting in plasmid pGJD3 (Fig. 1a). Experiments were
designed to use pVK43 initially but, due to difficulties
with the targeted restriction sites required to make
deletion mutants, it was more efficient to design cassettes
with truncated PCR products containing specific amino
acid residues expressed in a PCR2.1 TOPO plasmid using
E. coli DH5a as the host. The predicted amino acid
sequence of IDH 781 Aae was 96% identical to that of
Aae from strain CU 1000 (Fine et al., 2005). Nearly all of
the amino acid changes, including a 5 aa deletion in IDH
781, occurred in the region that encodes the C-terminal
half of the passenger domain, which was not related to
the functional binding region (Fig. 1a). The N-terminal
half of the passenger domain and the b domain were very
highly conserved (.99% identity, which showed differ-
ences in amino acids downstream of the functional
adhesin; see Supplementary Fig. S1, available with the
online version of this paper). The IDH 781 and CU 1000
Aae proteins both contained four copies of the char-
acteristic Aae amino acid repeat sequence (Fine et al.,
2005) (Fig. 1a).
A series of plasmids containing in-frame deletions in IDH
781 aae was also constructed (Fig. 1b). Plasmid pD68–594
contained a deletion of the entire passenger domain and
plasmid pD301–594 contained a deletion of the C-terminal
half of the passenger domain, including the four Aae amino
acid repeat sequences (Fig. 1b). Based on preliminary cell
binding assays with E. coli cells harbouring plasmids
pGJD3, pD68–594 and pD301–594 (Fig. 2a), we concluded
that the epithelial cell binding domain in Aae was located
between amino acids 68 and 301. We therefore constructed
a series of plasmids that encoded sequential deletions
within this region (pD301–594, pD284–594, pD264–594,
pD238–594, pD221–594, pD201–594, pD120–594 and
pD68–594) (Figs 1b and 2a).
Fig. 1. Physical maps of wild-type and mutant
A. actinomycetemcomitans Aae proteins. The
horizontal arrow in (a) represents the wild-type
Aae protein (907 aa). Also shown are a map of
the Aae protein domains (signal peptide,
passenger domain and b domain); the loca-
tions of amino acid difference between Aae
from strains CU 1000 and IDH 781; the
locations of the four characteristic Aae amino
acid repeat sequences; the location of the
sequence corresponding to the synthetic
peptides used to block Aae-mediated binding;
the locations of the Acc65I and Bpu10I
restriction sites used to construct Aae deletion
mutant plasmids; and a scale in amino acid
residues. (b) Physical maps of wild-type and
deletion mutant Aae proteins encoded by the
plasmids indicated on the left.
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proteins expressed in E. coli
We measured the binding ability of E. coli DH5a cells
harbouring pGJD3 and the eight aae deletion mutants
harbouring plasmids with deletions between amino acids
68 and 301 as listed above. In these experiments neither the
pCR2.1- (empty plasmid vector) nor the pD68–594-,
pD120–594-, or pD201–594-harbouring cells bound to
BECs, suggesting that amino acids 68–201 have nothing to
do with binding to epithelial cells. Modest binding was
restored in pD221–594-harbouring cells and almost half of
the total binding was restored in pD238–594-harbouring
cells, suggesting that residues 201–238 could be involved in
binding. Some modest additional binding was seen in
pD264–594-harbouring cells, while still greater binding was
restored in pD284–594-harbouring cells. Overall complete
restoration of binding was seen from amino acids 201 to
284, suggesting that the binding domain of interest should
include these amino acid residues (Fig. 2a).
Aae mediates bacterial binding to various oral
epithelial cells and vascular endothelial cells
We also measured the ability of E. coli cells harbouring Aae-
expressing plasmids to bind to OKF6/TERT-1, OBA9,
HUVEC and TW2.6 cells and BECs (Fig. 2b). Our goal was
to expand our assessment beyond BECs to cultured epithelial
cellsthatcouldbecollectedin a morecontrolled manner.For
convenience we limited our testing to plasmids that
expressed full-length Aae (pGJD3), no Aae (pD201–594),
truncations that produced minimal Aae (pD238–594), and
truncated proteins that restored Aae binding completely
(pD301–594). Complete reduction in binding was exhibited
by cells harbouring plasmid pD201–594, while minimal
binding was restored by plasmid pD238–594 when compared
to the full-length protein expressed by pGJD3. Binding was
fully restored by plasmid pD301–594. These data support the
hypothesis that amino acid residues from 301 to 594 have no
effect on binding and that the Aae epithelial binding domain
is located between amino acids 201 and 301. The BEC and
TW2.6 binding patterns of all Aae-harbouring plasmids
expressed in E. coli cells were similar, suggesting that TW2.6
cells could be used as surrogates for BECs (Fig. 2b).
We further compared binding of Aae expressed from
plasmids pVK43 and pGJD3 to BECs and TW2.6 cells (Fig.
2c). Our data show that Aae expressed from pVK43 bound
Fig. 2. Binding of plasmid-harbouring E. coli DH5a cells to freshly
isolated human BECs and cultured epithelial cells. (a) Binding of E.
coli harbouring the indicated plasmid expressing deletion mutant
Aae to BECs. Values show mean c.f.u. per epithelial cell for three
independent experiments and error bars indicate SD. Bars with
different letters indicate values that were significantly different from
each other by ANOVA and post-hoc pairwise testing. (b)
Comparison of binding of E. coli DH5a to cells of epithelial origin
when expressing Aae and truncated varieties of Aae proteins.
BECs, HUVECs, TERT, OBA9 and TW2.6 cells are compared.
Similarity between TW2.6 cells and BECs is seen when binding of
full-length Aae and truncated versions of Aae protein are
compared. Significant differences (P,0.05) for all cell types are
seen when full-length Aae is compared to 238–594 aa truncated
proteins. * Significantly lower binding to corresponding epithelial
cells versus full-length expressed Aae (pGJD3). (c) Direct
comparison of binding of E. coli DH5a to BECs and TW2.6 cells
when E. coli expresses aae from pVK43 versus pGJD3. Plasmid
pVK43 expressing Aae in DH5a binds at a higher level than that
seen for pGJD3. DH5a expressing 201–594, 221–594 and 238–
594 aa truncated proteins show significant reductions (P,0.05) in
binding to their corresponding epithelial cell type (* for BEC, 3 for
TW2.6 cells) when compared to DH5a expressing full-length
protein.
D. H. Fine and others
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(P,0.05). It is likely that plasmid expression levels are
responsible for these differences (Supplementary Figs S1,
S2). Nevertheless, binding differences between BECs and
TW2.6 cells were similar in both pVK43 and pCR2.1 cells,
reinforcing the sense that TW2.6 cells could act as a
reasonable surrogate for BECs.
Due to these results, and as a proof-of-principle strategy,
we chose to synthesize peptides derived from amino acid
sequences 201–221, 222–238 and 201–240 to test their
ability to reduce binding to epithelial cells. These peptides
were designed to test the principle that specific peptides
could be used to block Aae-mediated binding.
Peptides block binding of Aae to BECs
Only the 40-mer (P40), as opposed to P17 or P21, blocked
binding of the Aae harboured in plasmid pVK43 and
expressed in E. coli (Fig. 3a). No effect was seen by pre-
treating BECs with either the 17-mer or the 21-mer. This
result differs from that seen when the truncated proteins
are expressed in E. coli. Differences could result from
conformational distinctions between the expressed proteins
and the synthesized peptides. It was shown that P40
peptide pre-treatment can reduce binding of both the full-
length (pGJD3) and the truncated Aae proteins (pD238–
594, pD221–594; P,0.05) (Fig. 3b). These results suggest
that both the full-length and the truncated proteins are
surface expressed. Fig. 3(c) illustrates the effect of the P40
peptide on Aae expression in Aa strain JK 1047, an flp-
mutant strain (Table 1). Here, bacterial binding is reduced
from 14 to 2 JK 1047 cells BEC
21 (P,0.05). Neither the
17-mer nor the 21-mer, nor pre-treatment with BSA, had
any effect on binding of JK 1047 to BECs. This Flp-negative
strain was used because, unlike the parent wild-type strain
(IDH 781), JK 1047 does not autoaggregate. As a result, JK
1047 provides a way to measure receptor–adhesin inter-
action in native Aa strains not showing autoaggregation.
The P40 peptide pre-treatment of both the BECs and TW2.6
cellsreducedbindinginadose-dependentmanner,asshown
in Fig. 4(a). Peptide levels of 1.0 mM and above significantly
reduced binding (P,0.05). A fluorescently labelled P40
peptide was used to demonstrate that P40 bound to TW2.6
cells in a dose-dependent manner, showing a trend toward
saturation (Fig. 4b). These findings suggest that peptide P40
blocked the interaction of Aae with its BEC receptor by
binding it in a dose-dependent manner.
DISCUSSION
Several years ago, receptor and adhesin analogue therapy or
anti-adhesive therapy was introduced as a new way of
interfering with mucosal infections (Aronson et al., 1979;
Beachey & Courtney, 1987; Cheney et al., 1980; Simpson &
Beachey, 1983). The premise suggested that by blocking
bacterial–tissue interactions, anti-adhesive therapy could
alter the manifestation of disease without the need to kill
the infecting micro-organism (Sellwood et al., 1975;
Fig. 3. Effect of synthetic peptides on Aae binding to epithelial cells.
(a) BECs were pre-treated with 17-mer, 21-mer and 40-mer (P40)
peptides at a dose of 100 mM. Reduction in binding is seen only in
the case of P40. * Significantly lower (P,0.05) binding by ANOVA.
(b) EffectofP40 peptideonthe ability of E.coliexpressingtruncated
proteins to bind to BECs. The data show that binding is reduced by
pre-treatment of BECs with P40 peptide, indicating surface
expression of truncated proteins. Peptide was added at 100 mM.
*, P,0.05. (c) Effect of various peptides (17-, 21- and 40-mer) on
binding of Aa strain JK 1047 (flp-mutant expressing aae and apiA)t o
BECs. Pre-treatment of BECs with P40 significantly (* P,0.05)
reduces binding of JK 1047 at the concentration of JK 1047 added.
Only the P40 peptide reduced binding. All experiments were done in
triplicate and values are expressed as means±SD.
A. actinomycetemcomitans autotransporter adhesin
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report were designed to revisit the anti-adhesive thera-
peutic approach in relation to Aa-induced infections.
Aa expresses two autotransporter adhesins, Aae and ApiA,
that are involved in mucosal binding (Fine et al., 2006). It
is interesting to note that the two autotransporter adhesins
show specificity for the same epithelial tissue surfaces and
mammalian species (Yue et al., 2007). Since both Aae and
ApiA mediate Aa binding to BECs, perhaps a functional
overlap exists between these two autotransporters. This
overlap or redundancy could suggest that BEC binding is of
great importance to the survival of Aa in the mucosal
domain of the oral cavity of humans and Old World
primates. While this area needs further exploration it is
known that Aae binds at low cell density while ApiA binds
only at high cell density (Fine et al., 2005). Since both
autotransporter adhesins are involved in binding to BECs,
our effort to block Aa binding by interfering with one
adhesin could prove to be a challenge.
This potential redundancy has led us to think of these
autotransporters in the context of the temporal events
associated with mucosal infections. In the early stages of
infection, during the incubation and prodromal periods, Aa
would be present at low cell densities, but as disease ensues,
Aa cell densities would increase in the local environment
(Fine et al., 2006). Since our P40 peptide functioned better
at low cell density (the data shown in Fig. 3 were obtained at
a low density of added cells) we would predict that it would
be effective in the early stages of infection. In contrast,
minimal reduction of BEC binding by peptide P40 was seen
when Aa cells were added at a high density since ApiA was
also active (data not shown), suggesting that our peptide
would be minimally effective as a therapeutic intervention.
This area also needs further exploration.
The Aae passenger domain is displayed on the cell surface
and thus would appear to be capable of interacting with the
outside environment (Fine et al., 2005). Our experimental
data, and those of others, have indicated that Aa strains
have passenger domains containing repeat sequences that
vary in the number of repeat motifs (Fine et al., 2005; Rose
et al., 2003). As a result we have tried to assess the
functional changes in binding related to these repeats (Fine
et al., 2006; Henderson et al., 2004). While Rose et al.
(2003) proposed that increasing the number of Aae repeats
results in increased binding, data from the current study do
not support this contention. Our results suggest that Aae-
mediated binding to BECs resides between amino acids
201–284 and lies immediately upstream of the Aae repeat
domain. We have also observed that different strains of Aa,
differing in the number of Aae repeats, do not differ in the
amount of binding seen (data not shown).
In our studies, the P40 peptide reduced binding to BECs by
at least 50% (Fig. 3a–c). There are at least two possible
explanations that can be offered as to why the P40 peptide
did not completely abrogate Aae-mediated binding. First,
the P40 peptide does not represent the Aae protein adhesin
binding domain in its entirety (Fig. 2a). Second, since
conformational differences exist between peptides and
expressed proteins, the peptides may not provide a
completely accurate representation of the Aae protein
adhesin. This second point may not be valid since our
Fig. 4. Dose-dependent interaction of P40 peptide with BECs and
TW2.6 cells. (a) Effect of P40 pre-treatment of BECs and TW2.6
cells on binding of A. actinomycetemcomitans JK 1047. P40
doses of 1.0, 10 and 100 mM show significant reductions in
binding (P,0.05), indicating a P40 dose-dependent inhibition of
binding to BECs and TW2.6 cells. Bars with different letters are
significantly different from each other by ANOVA and post-hoc
pairwise testing. (b) Fluorescently labelled peptide P40 binds to
TW2.6 cells in a dose-dependent manner. TW2.6 cells were
treated with increasing concentrations of labelled peptide. The
amount of fluorescence as measured suggests saturation of
TW2.6 receptor sites. Blank wells (untreated TW2.6) were used
as control (data not shown). Data are presented as the means±SD
of three independent experiements.
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reduction in binding when compared to the truncated
protein as expressed in E. coli. These issues will be resolved
in future studies.
In conclusion, we have evidence that within the Aae
autotransporter adhesin domain there is a motif of 40 aa
that accounts for a large percentage of its interaction with
epithelial cells. Our effort was to evaluate this 40 aa
sequence and to translate this information into a strategy
that could be used to interfere with Aa binding.
Experiments presented in this report were first performed
by deletion analysis and then confirmed by peptide
blocking studies. While the information obtained does
not account for the entire binding capacity of Aa to the
epithelium, it should suggest ways to design future
experiments. Our long-term goal is to discover ways to
completely block the binding of this oral pathogen to its
target tissue and thus develop methods for anti-adhesive
therapy.
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